InflaRx N.V.
$1.66
▲
1.04%
2026-04-21 07:28:00
www.inflarx.de
NMS: IFRX
Explore InflaRx N.V. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$120.01 M
Current Price
$1.66
52W High / Low
$1.94 / $0.71
Stock P/E
—
Book Value
$0.67
Dividend Yield
—
ROCE
-114.26%
ROE
-88.63%
Face Value
—
EPS
$-0.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
65
Beta
1.51
Debt / Equity
2.16
Current Ratio
4.13
Quick Ratio
4.13
Forward P/E
-1.33
Price / Sales
2,464.73
Enterprise Value
$26.73 M
EV / EBITDA
-0.56
EV / Revenue
911.44
Rating
Buy
Target Price
$8.94
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zenas BioPharma, Inc. | $20.9 | — | $1.28 B | — | -65.85% | -1.36% | $44.6 / $8.09 | $4.44 |
| 2. | MediWound Ltd. | $17.35 | — | $226.34 M | — | -41.75% | -63.86% | $22.5 / $14.9 | $3.4 |
| 3. | Vanda Pharmaceuticals Inc. | $6.99 | — | $417.3 M | — | -43.97% | -50.93% | $9.94 / $3.81 | $5.54 |
| 4. | Oramed Pharmaceuticals Inc. | $3.83 | 3.45 | $151.27 M | 0% | -7.12% | 37.1% | $3.96 / $1.98 | $4.98 |
| 5. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
| 6. | GH Research PLC | $21.5 | — | $1.33 B | — | -21.68% | -21.04% | $24.66 / $8.66 | $4.51 |
| 7. | RenovoRx, Inc. | $1 | — | $45.05 M | — | -176.68% | -2.26% | $1.45 / $0.7 | $0.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | -0.03 M | 0.02 M | 0.04 M | 0 M | -0 M | — |
| Operating Profit | -12.86 M | -9.48 M | -12.83 M | -13.01 M | -9.76 M | — |
| Net Profit | -10.64 M | -12.26 M | -14.42 M | -8.31 M | -5.11 M | — |
| EPS in Rs | -0.15 | -0.17 | -0.2 | -0.12 | -0.07 | -0.3 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.03 M | 0.17 M | 0.06 M | 0 M |
| Operating Profit | -48.26 M | -52.91 M | -44.59 M | -32.24 M |
| Net Profit | -45.63 M | -46.06 M | -42.67 M | -29.48 M |
| EPS in Rs | -0.63 | -0.64 | -0.59 | -0.41 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 55.22 M | 76.02 M | 120.21 M | 102.4 M |
| Total Liabilities | 13.66 M | 14.6 M | 17.63 M | 14.05 M |
| Equity | 41.56 M | 61.42 M | 102.58 M | 88.35 M |
| Current Assets | 53.63 M | 71.66 M | 109.47 M | 97.41 M |
| Current Liabilities | 12.98 M | 14.17 M | 16.84 M | 13.03 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -35.31 M | -48.56 M | -37.81 M | -33.74 M |
| Investing CF | 3.23 M | 52.36 M | -17.7 M | 19.36 M |
| Financing CF | 33.32 M | 0.39 M | 52.99 M | 1.94 M |
| Free CF | -35.43 M | -48.6 M | -37.89 M | -33.91 M |
| Capex | -0.12 M | -0.05 M | -0.08 M | -0.16 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -82.31% | 162.79% | — | — |
| Earnings Growth % | 0.93% | -7.96% | -44.71% | — |
| Profit Margin % | -155582.08% | -27784.96% | -67630.69% | — |
| Operating Margin % | -164525.5% | -31911.39% | -70685.63% | — |
| Gross Margin % | -24677.94% | -1900.76% | -743.67% | — |
| EBITDA Margin % | -153976.26% | -27476.74% | -66674.26% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.